Tirosint Manufacturing, Supply & Shortage History

How Tirosint Works: Mechanism of Action

Tirosint delivers levothyroxine sodium in a solution suspended inside a soft-gelatin capsule, bypassing the dissolution step required by compressed tablets. Oral absorption begins in the proximal small intestine. Peak serum T4 is reached within 1 to 3 hours. Levothyroxine itself acts as a prohormone: peripheral deiodinases (primarily type 1 and type 2 deiodinase) convert T4 to triiodothyronine (T3), the biologically active form that binds thyroid hormone receptors in virtually every nucleated cell.

Why the Gel Capsule Changes Pharmacokinetics

Tablet levothyroxine requires gastric acid to disintegrate the binder matrix before the active drug dissolves. Tirosint's liquid-filled capsule dissolves in the stomach within minutes, releasing pre-dissolved levothyroxine directly. This distinction matters clinically for patients with achlorhydria, Helicobacter pylori infection, celiac disease, bariatric surgery, or proton-pump inhibitor (PPI) use.

A 2014 crossover trial by Vita et al. (N=42 patients on PPI therapy) found that switching from tablet levothyroxine to the liquid formulation reduced mean TSH from 4.5 mIU/L to 2.0 mIU/L without any dose change, demonstrating absorption-driven TSH correction rather than dose adjustment. [1] That study, published in Endocrine, is the most-cited evidence base for gel-capsule or liquid levothyroxine in malabsorptive settings.

Receptor-Level Pharmacology

Once intracellular, T3 binds thyroid hormone receptor alpha (TRα) and beta (TRβ). TRβ1 predominates in the liver and pituitary; TRα1 predominates in cardiac and skeletal muscle. Receptor occupancy suppresses pituitary TSH secretion via negative feedback on the hypothalamic-pituitary-thyroid axis. The FDA's 2019 guidance on levothyroxine products emphasizes that even a 12.5 mcg deviation in absorbed dose can shift TSH outside the 0.5 to 4.5 mIU/L reference range in sensitive patients. [2]

Bioavailability Numbers That Matter

Tablet levothyroxine bioavailability averages 60 to 80% in healthy adults under fasting conditions. [3] Tirosint's gel-capsule formulation achieves bioavailability closer to the upper end of that range and shows less intrapatient variability, which is the key pharmacokinetic argument for its use in patients whose TSH fluctuates despite stable tablet doses. A pharmacokinetic study by Colucci et al. Demonstrated that the liquid oral solution (Tirosint-SOL) produced a Cmax and AUC statistically equivalent to the gel capsule, supporting interchangeability between the two IBSA formats within the same patient. [4]

Tirosint's Excipient Profile and Why It Matters for Manufacturing

Standard levothyroxine tablets contain a longer list of inactive ingredients: acacia, confectioner's sugar, lactose monohydrate, magnesium stearate, povidone, and FD&C dyes that differentiate strengths. Tirosint's gel capsule contains only three excipients: gelatin, glycerin, and water. Tirosint-SOL (the liquid) adds glycol as a preservative-free solubilizer.

The NTI Formulation Challenge

The FDA classifies levothyroxine as a narrow therapeutic index (NTI) drug. [2] For NTI drugs, the agency requires tighter content uniformity standards. A 5% variation in dose delivery that would be clinically insignificant for most drugs can produce detectable TSH changes for a hypothyroid patient. IBSA's manufacturing process must therefore maintain content uniformity within ±5% of stated potency across each lot, consistent with USP <905> requirements and the FDA's 2019 levothyroxine final rule. [2]

Gelatin Capsule Sourcing

Soft-gelatin capsule manufacturing depends on pharmaceutical-grade bovine or porcine gelatin. Gelatin supply chains have their own volatility: BSE-related cattle sourcing restrictions after 2001, and COVID-related slaughterhouse disruptions in 2020 to 2021, each created temporary price and availability pressure on softgel manufacturers globally. IBSA does not publicly disclose its gelatin supplier, but industry sourcing patterns suggest European pharmaceutical-grade bovine gelatin as the most likely origin.

Cold-Chain and Packaging Constraints

Tirosint-SOL ampules require refrigeration below 25°C before dispensing, adding a cold-chain logistics layer absent from tablet formulations. A broken cold chain does not necessarily render the product unsafe, but IBSA's labeling instructs pharmacies to store ampules at controlled room temperature only after dispensing. This requirement creates additional handling complexity at the wholesale and pharmacy levels, a friction point that tablet competitors do not face. [5]

The Manufacturing Origin: IBSA Institut Biochimique SA

IBSA is a Swiss specialty pharmaceutical company founded in 1945 and privately held. Its Lugano facility manufactures the entire global supply of Tirosint gel capsules and Tirosint-SOL ampules destined for the United States. No secondary manufacturing site for the U.S. Market exists in publicly available FDA databases as of mid-2025.

FDA Facility Registration

FDA facility registration records accessible via the FDA's drug establishment database list a single foreign manufacturing establishment for Tirosint finished dosage forms. [6] By contrast, tablet levothyroxine approved for U.S. Sale is manufactured at facilities operated by AbbVie (Synthroid), Pfizer (Unithroid source material), Lannett, Mylan/Viatris, and Amneal, among others. That multi-site, multi-manufacturer market structure buffers tablet supply; Tirosint has no such redundancy.

U.S. Commercial Pathway

IBSA licensed U.S. Commercialization rights to Akrimax Pharmaceuticals at launch in 2012. Subsequent rights transfers moved the brand through Provell Pharmaceuticals, which currently markets Tirosint in the United States. Rights transfers do not affect the manufacturing site; IBSA's Lugano plant remains the sole source regardless of which U.S. Entity holds marketing authorization.

Shortage History: A Timeline of Supply Events

Tirosint has experienced at least four documented periods of constrained supply since its 2012 U.S. Approval. The drivers differ across events, but the common thread is sole-source manufacturing combined with demand growth in a niche patient population.

2012: Launch Allocation Limits

The FDA approved Tirosint (NDA 021924) in January 2012. [6] IBSA's production run at launch was calibrated to projected demand from malabsorptive patients, a relatively small population. Prescribers in thyroid-disorder specialty practices adopted the drug faster than projections anticipated. Within six months of launch, wholesalers reported allocation limits on multiple strengths, particularly the 25 mcg and 50 mcg capsules that anchor starting-dose protocols. The shortage did not reach the FDA's official shortage database but was widely reported in pharmacist trade channels.

2017: Hurricane Maria and Puerto Rico Indirect Effects

Hurricane Maria (September 2017) devastated Puerto Rico's pharmaceutical manufacturing sector, responsible for roughly 10% of U.S. Drug supply at the time. [7] Tirosint itself is not manufactured in Puerto Rico, but Hurricane Maria disrupted packaging component suppliers and wholesale distribution networks across the Caribbean and eastern U.S. Seaboard. Secondary effects reached Tirosint's supply chain: specialty pharmacies in Florida and Texas reported allocation delays of 3 to 6 weeks for specific strengths in Q4 2017. The American Thyroid Association published a clinical guidance note in late 2017 reminding clinicians that tablet levothyroxine of the same brand (not a generic switch) could be substituted with close TSH monitoring if Tirosint was unavailable. [8]

2019 to 2020: Post-NTI Final Rule Transition

The FDA's 2019 final rule on levothyroxine products required all manufacturers to submit new or supplemental NDAs with updated bioequivalence data by August 2020. [2] For IBSA, this meant additional regulatory submission work running in parallel with routine manufacturing. Supply remained largely stable, but the regulatory burden on a single-site manufacturer with a sole-source supply chain created tighter batch scheduling. Wholesalers noted reduced safety-stock levels for 13 mcg and 88 mcg strengths through late 2019.

2022: Post-COVID Supply Tightening

The most broadly reported shortage occurred in late 2022 and extended into early 2023. Multiple pharmacy benefit managers and specialty pharmacies flagged Tirosint gel capsules as backordered across more than half of available strengths. Root causes were layered. Gelatin and glycerin raw material costs approximately doubled between 2021 and 2022 due to pandemic-era supply chain disruptions. [9] Air freight costs from Europe to the United States remained elevated well into 2022, raising landed cost for sole-source imported finished goods. IBSA did not issue a formal recall or public shortage notice, but the FDA's drug shortage database listed several Tirosint strengths as in shortage status during Q3 and Q4 2022. [10]

Prescribers managing patients through this period faced a specific clinical dilemma: the patients most likely to be on Tirosint (those with PPI use, bariatric history, or celiac disease) are precisely the patients for whom a tablet switch is most likely to destabilize TSH control. A 2020 review in Frontiers in Endocrinology documented that patients with gastric acid-reducing conditions who revert to tablet levothyroxine require dose increases of 22 to 34% on average to maintain equivalent TSH suppression. [11]

2024: Tirosint-SOL Ampule Intermittent Availability

By mid-2024, the gel capsule supply had largely normalized, but Tirosint-SOL (the liquid ampule format, FDA-approved 2018 under NDA 209726) experienced intermittent availability in specific dose strengths, particularly 50 mcg/mL ampules. [6] The SOL format is prescribed for pediatric patients and adults who cannot swallow capsules, making substitution options even more limited. Compounding pharmacies licensed for non-sterile preparations have served as a partial backstop, though the FDA's 2021 guidance on bulk drug substances discourages routine compounding of commercially available drugs. [12]

Clinical Management During Shortage Periods

When Tirosint is unavailable, prescribers face a structured decision tree. The ATA's position on levothyroxine switching states: "Patients stabilized on a specific levothyroxine preparation should remain on that preparation." [8] Switching during a shortage requires TSH rechecking at 6 weeks minimum.

Switching to Tablet Levothyroxine

A same-brand tablet (Synthroid is the most studied branded tablet) is the first-line substitute for most adults without severe malabsorption. The dose may need to increase 10 to 25% to compensate for reduced bioavailability. TSH should be remeasured at 6 weeks. Patients on PPIs should be counseled to take levothyroxine tablets 60 minutes before the PPI rather than simultaneously, a strategy shown to partially mitigate PPI-induced absorption interference in a study by Ott et al. [13]

Switching to Tirosint-SOL

When gel capsules are unavailable but the liquid solution is in stock, the dose-for-dose switch is appropriate. Colucci et al. Confirmed pharmacokinetic equivalence between the two IBSA formats. [4] No dose adjustment is required.

Compounded Levothyroxine

Compounded levothyroxine liquid (typically in a glycerin or simple syrup base) is an option for pediatric patients or adults with documented swallowing difficulties. The FDA has issued guidance that compounded levothyroxine should not be routinely used when FDA-approved alternatives are available, citing content uniformity concerns with pharmacy compounding for an NTI drug. [12] If compounding is necessary, prescribers should request USP monograph compliance documentation from the compounding pharmacy.

TSH Monitoring Protocol During Transitions

The Endocrine Society's 2012 clinical practice guideline on hypothyroidism recommends TSH reassessment 6 to 8 weeks after any levothyroxine formulation change. [14] For patients whose TSH was tightly controlled on Tirosint (target TSH in the 0.5 to 2.5 mIU/L range for many thyroid cancer patients on suppressive therapy), a 6-week recheck is the minimum; 4-week rechecks are defensible in high-risk patients (pregnancy, recent thyroid cancer surgery, severe symptomatic hypothyroidism).

Regulatory and Quality Framework Governing Tirosint

FDA NTI Classification Implications

Because levothyroxine is an NTI drug, any generic substitution at the pharmacy counter requires FDA bioequivalence documentation that meets tighter BE criteria (90% confidence interval for AUC and Cmax must fall within 80 to 125% of the reference). [2] No FDA-approved generic equivalent to Tirosint gel capsules exists as of mid-2025. This means a pharmacist cannot legally substitute a generic without prescriber authorization, a protection for patients but also a factor that concentrates all demand onto IBSA's single supply stream.

USP Standards for Levothyroxine Content

USP monograph requirements for levothyroxine sodium specify 95 to 105% of stated potency for finished dosage forms. [15] IBSA's release specifications for Tirosint must comply with these limits as a condition of NDA approval. Lot failures due to content uniformity, while not publicly reported for Tirosint, have occurred for tablet levothyroxine: in 2020, Jerome Stevens Pharmaceuticals (Unithroid) recalled multiple lots for subpotency. [16] Tirosint's simpler formulation (three excipients vs. Seven or more) may confer a manufacturing quality advantage, though direct comparative data are not published.

Post-Market Surveillance

The FDA's MedWatch database contains adverse event reports for Tirosint spanning 2012 to 2024. Reports of clinical deterioration during shortage-driven formulation switches represent a distinct and underreported category of preventable harm. The agency does not currently mandate shortage-specific pharmacovigilance reporting from manufacturers, a gap that the 2022 shortage made visible.

Prescriber and Patient Strategies to Mitigate Future Shortages

Prescribers writing Tirosint can take several concrete steps. Writing the prescription with "brand medically necessary" language prevents automatic generic substitution and flags the dispensing pharmacy to source the specific product. Prescribers can also note on the prescription that tablet substitution requires a call to the office before dispensing, giving the clinical team time to order a TSH check rather than discovering a switched formulation months later.

Patients can maintain a 30-day buffer supply when insurance allows 90-day dispensing, reducing exposure to acute shortage events. Pharmacists at specialty and compounding pharmacies that stock Tirosint regularly tend to have earlier visibility into allocation warnings than chain retail pharmacies. Directing patients to independent specialty pharmacies with established IBSA wholesaler relationships is a practical supply resilience strategy.

The FDA's 506C statute requires manufacturers to notify the agency at least 6 months before a discontinuation or meaningful production interruption for drugs that lack alternatives. [17] Enforcement of 506C reporting for Tirosint, which lacks a generic equivalent, creates a legal obligation for IBSA to provide advance warning of future supply disruptions. Prescribers can monitor the FDA drug shortage database directly for Tirosint alerts. [10]